~/blog/fda-mandatory-gras-notices-proposed-rule
FDA proposes making GRAS notices mandatory, with comments open to 9 December
A proposed rule published on 11 August would require companies to file notices for food substances they have concluded are generally recognised as safe. What it would reach on a nootropics shelf, and what it plainly would not.
An unfamiliar ingredient can turn up in a functional coffee or a focus gummy without any agency ever seeing a piece of paper about it. That is the design of the system, not a loophole in it. On 11 August the FDA proposed changing it.
The document is a proposed rule on substances generally recognised as safe, Docket No. FDA-2025-N-3262 and RIN 0910-AJ02. It would require GRAS notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use.
What would change
Today a company can reach what the notice calls an independent conclusion of GRAS status — one arrived at without submitting a notice — and take the ingredient to market. The summary of major provisions describes the aim as to “convert the voluntary GRAS notification program to a mandatory” one, subject to certain exceptions, with non-compliance counting as a factor when the agency prioritises substances for post-market review.
The notice gives its own background: in March 2025 the Secretary of Health and Human Services directed FDA to explore rulemaking to close the route by which firms introduce purported GRAS uses without notifying the agency. It also cites GAO’s 2010 report on FDA’s oversight of GRAS ingredients, which recorded one firm making about five such conclusions a year without telling the agency.
The scope, stated carefully
This is a food rule, covering substances added to human or animal food and food-contact substances. It is not a supplement rule, and the text runs explicitly the other way: an ingredient described in section 201(ff) of the FD&C Act, intended for use in a dietary supplement, sits outside the food-additive definition and so is not eligible for GRAS classification under that provision at all.
The relevance here is an adjacency, not a direct effect. Much of what a label-reader meets in this category is not sold as a supplement at all — it arrives in a canned drink, a coffee, a chew, as food. Those uses are where independent GRAS conclusions live, and a mandatory filing would make that reasoning visible outside the firm that reached it. The dose still would not be disclosed on the panel; the safety basis would stop being private.
What it is not, yet
A proposal is a proposal. Comments run to 9 December 2026, no effective or compliance date is settled, and a final rule can differ from the published one.
And since the agency’s name is doing heavy lifting above: a filing is a transparency mechanism, not a verdict on whether anything works. Supplements are not evaluated by the FDA, are not intended to diagnose, treat, cure or prevent any disease, and nothing here replaces a clinician’s view on what you are already taking.